Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2004-06-24
2008-08-19
Canella, Karen A. (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S004000, C435S007200, C435S007210, C435S007230
Reexamination Certificate
active
07413864
ABSTRACT:
The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
REFERENCES:
patent: 3817837 (1974-06-01), Tanenholtz et al.
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 3939350 (1976-02-01), Kronick et al.
patent: 3996345 (1976-12-01), Ullman et al.
patent: 4275149 (1981-06-01), Litman et al.
patent: 4277437 (1981-07-01), Maggio
patent: 4366241 (1982-12-01), Tom et al.
patent: 4554101 (1985-11-01), Hopp
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4965188 (1990-10-01), Mullis et al.
patent: 5001225 (1991-03-01), Taylor
patent: 5075227 (1991-12-01), Hagen
patent: 5489508 (1996-02-01), West et al.
patent: 5583016 (1996-12-01), Villeponteau et al.
patent: 5597697 (1997-01-01), Diamond
patent: 5639613 (1997-06-01), Shay et al.
patent: 5747317 (1998-05-01), Cao
patent: 5770422 (1998-06-01), Collins
patent: 5853719 (1998-12-01), Nair et al.
patent: 5917025 (1999-06-01), Collins
patent: 5919656 (1999-07-01), Harrington et al.
patent: 5919676 (1999-07-01), Graham et al.
patent: 6093809 (2000-07-01), Cech et al.
patent: 6120764 (2000-09-01), Graham et al.
patent: 6140087 (2000-10-01), Graham et al.
patent: 6166178 (2000-12-01), Cech et al.
patent: 6258535 (2001-07-01), Villeponteau et al.
patent: 6261556 (2001-07-01), Weinrich et al.
patent: 6261836 (2001-07-01), Cech et al.
patent: 6306388 (2001-10-01), Nair et al.
patent: 6309867 (2001-10-01), Cech et al.
patent: 6337200 (2002-01-01), Morin
patent: 6387701 (2002-05-01), Nair et al.
patent: 6440735 (2002-08-01), Gaeta
patent: 6444650 (2002-09-01), Cech et al.
patent: 6475789 (2002-11-01), Cech et al.
patent: 6517834 (2003-02-01), Weinrich et al.
patent: 6545133 (2003-04-01), Weinrich et al.
patent: 6608188 (2003-08-01), Tsuchiya et al.
patent: 6610839 (2003-08-01), Morin et al.
patent: 6617110 (2003-09-01), Cech et al.
patent: 6627619 (2003-09-01), Cech et al.
patent: 6767719 (2004-07-01), Morin et al.
patent: 6777203 (2004-08-01), Morin et al.
patent: 6787133 (2004-09-01), Weinrich et al.
patent: 6808880 (2004-10-01), Cech et al.
patent: 6921664 (2005-07-01), Cech et al.
patent: 6927285 (2005-08-01), Cech et al.
patent: 7005262 (2006-02-01), Cech et al.
patent: 7056513 (2006-06-01), Cech et al.
patent: 7091021 (2006-08-01), Morin
patent: 7195911 (2007-03-01), Cech et al.
patent: 7262174 (2007-08-01), Jiang et al.
patent: 7262288 (2007-08-01), Cech et al.
patent: 7285639 (2007-10-01), Cech et al.
patent: 2002/0164786 (2002-11-01), Cech et al.
patent: 2002/0187471 (2002-12-01), Cech et al.
patent: 2003/0009019 (2003-01-01), Cech et al.
patent: 2003/0032075 (2003-02-01), Cech et al.
patent: 2003/0044953 (2003-03-01), Cech et al.
patent: 2003/0059787 (2003-03-01), Cech et al.
patent: 2003/0096344 (2003-05-01), Cech et al.
patent: 2003/0100093 (2003-05-01), Cech et al.
patent: 2004/0247613 (2004-12-01), Cech et al.
patent: 2194393 (1996-01-01), None
patent: 2271718 (1998-05-01), None
patent: 2 317 891 (1998-04-01), None
patent: 9154575 (1997-06-01), None
patent: WO 82/01461 (1982-05-01), None
patent: WO 84/03564 (1984-09-01), None
patent: WO 93/23572 (1993-11-01), None
patent: WO 94/17210 (1994-08-01), None
patent: WO 95/13382 (1995-05-01), None
patent: WO 96/01835 (1996-01-01), None
patent: WO 96/12811 (1996-05-01), None
patent: WO 96/19580 (1996-06-01), None
patent: WO 96/40868 (1996-12-01), None
patent: WO 97/38013 (1997-10-01), None
patent: WO 98/01542 (1998-01-01), None
patent: WO 98/01543 (1998-01-01), None
patent: WO 98/07838 (1998-02-01), None
patent: WO 98/08938 (1998-03-01), None
patent: WO 98/14592 (1998-04-01), None
patent: WO 98/14593 (1998-04-01), None
patent: WO 98/21343 (1998-05-01), None
patent: WO 98/23759 (1998-06-01), None
patent: WO 98/37181 (1998-08-01), None
patent: WO 98/45450 (1998-10-01), None
patent: WO 98/59040 (1998-12-01), None
patent: WO 99/01580 (1999-01-01), None
patent: WO 99/33998 (1999-07-01), None
patent: WO 99/38964 (1999-08-01), None
patent: WO 99/63945 (1999-12-01), None
patent: WO 00/02581 (2000-01-01), None
patent: WO 00/46355 (2000-08-01), None
patent: WO 00/61766 (2000-10-01), None
patent: WO 00/73420 (2000-12-01), None
patent: WO 01/60391 (2001-08-01), None
patent: WO 02/094213 (2002-11-01), None
patent: WO 03/038047 (2003-05-01), None
Nair et al., J. Immunol 2000 165(12): 6949-6955.
Roitt et al (Immunology, 1993, Mosby, St. Louis, p. 6.4-6.5).
Roitt et al (Immunology, 1993, Mosby, St. Louis, p. 7.7-7.8).
Greenspan et al (Nature Biotechnology, 1999, 7:936-937).
Bowie et al (Science, 1990, 257:1306-1310).
Herbert et al (The Dictionary of Immunology, Academic Press, 3rd Edition, London, 1985, pp. 58-59).
Holmes (Exp. Opin.Invest. Drugs, 2001, 10(3):511-519).
Yi et al (Nucleic acids Research, 2001, 23:4818I-4825).
Krams et al (Am. J. Pathol., 2001, 159:1925-1932).
Hirashima (Int. Arch. Allergy Immunol., 2000, Suppl 1:6-9).
Benedict et al (J. Exp. Medicine, 2001, 193(1)89-99).
Jiang et al (JBC, 2003, 278(7) 4763-4769.
Burgess et al (J of Cell Bio. 111:2129-2138, 1990).
Lazar et al (Molecular and Cellular Biology, 1988, 8:1247-1252).
U.S. Appl. No. 10/877,124, Cech et al.
U.S. Appl. No. 10/877,146, Cech et al.
Anderson, W. French “Human Gene Therapy”Nature, Apr. 30, 1998, pp. 25-30, vol. 392, Supp.
Campbell, Keith & Wilmut, Ian “Totipotency or Multipotentiality of Cultured Cells: Applications and Progress” Theriogenology, Jan. 1997, pp. 63-72, vol. 47, Issue 1, Elsevier Science Inc.
Gearhart, John “New Potential for Human Embryonic Stem Cells”Science, Nov. 6, 1998; pp. 1061-1062, vol. 282, Issue 5391.
Hornsby, PJ et al. “Adrenocortical Cells Immortalized by Telomerase: Potential Use forEx VivoGene Therapy” Journal of Anti-Aging Medicine, 2000, pp. 411-417, vol. 3, No. 4.
Ostler Elizabeth L. et al. “Telomerase and the Cellular Lifespan: Implications for the Aging Process” J. of Pediatric Endocrinology & Metabolism, 2000, pp. 1467-1476, vol. 13, Supplement 6, Freund Publishing House Ltd. London.
Thomson, James A. et al. “Embryonic Stem Cell Lines Derived from Human Blastocysts”Science, Nov. 6, 1998; pp. 1145-1147, vol. 282, Issue 5391.
Adams, Mark et al. “Initial Assessment of Human Gene Diversity and Expression Patterns Based Upon 83 Million Nucleotides of cDNA Sequence”The Genome Directory: Supplement to NetureSep. 28, 1995, 1995, pp. 3-174, vol. 377, Issue 6547S.
Adamson, D. et al. “Significant Telomere Shortening in Childhood Leukemia”,Cancer Genet. Cytogenet, 1992; pp. 204-206, vol. 61.
Anderson and Young, “Quantitative Filter Hybridization” inNucleic Acid Hybridizationpp. 73-111 (1985).
Ausubel, F. et al., Current Protocols in Molecular Biology, 1996, vol. 1, Chapter 5, John Wiley & Sons, New York NY.
Autexier, C. & Greider, C. Telomerase and cancer: revisiting the telomere hypothesis; Trends in Biochemical Sciences, 1996, pp. 387-391, vol. 10, No. 21.
Autexier, C. et al., “Reconstitution of human telomerase activity and identification of a minimal functional region of the human telomerase RNA,”EMBO J, 1996, pp. 5928-5935, vol. 15.
Auxexier and Greider, “Functional reconstitution of wild-type and mutantTetrahymenatelomerase,”Genes Develop., 1994, pp. 563, vol. 8.
Avilion, A., “Characterization and expression of human telomerase,” Dissertation Abstracts International, 1996, pp. 5930-B, vol. 56, No. 11.
Bandyopadhyay et al. “The human melanocyte: a model system to study the complecity of cellular aging and transformation in non-fibroblastic cells”,Exp. Gerontol., 2001, pp. 1265, vol. 36.
Baringa, Marcia, “The
Andrews William H.
Cech Thomas R.
Chapman Karen B.
Harley Calvin B.
Lingner Joachim
Canella Karen A.
Geron Corporation
Reddig Peter J
The Regents of the University of Colorado
Townsend and Townsend / and Crew LLP
LandOfFree
Treating cancer using a telomerase vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treating cancer using a telomerase vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating cancer using a telomerase vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4019490